Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Net Margin (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Net Margin for 12 consecutive years, with 32657.69% as the latest value for Q1 2026.

  • For Q1 2026, Net Margin fell 3085097.0% year-over-year to 32657.69%; the TTM value through Mar 2026 reached 11859.13%, up 1200758.0%, while the annual FY2025 figure was 32575.5%, 3237318.0% down from the prior year.
  • Net Margin hit 32657.69% in Q1 2026 for Cartesian Therapeutics, down from 5335.93% in the prior quarter.
  • Across five years, Net Margin topped out at 5335.93% in Q4 2025 and bottomed at 32657.69% in Q1 2026.
  • Average Net Margin over 5 years is 2421.16%, with a median of 173.02% recorded in 2023.
  • Year-over-year, Net Margin soared 411691bps in 2024 and then crashed -3085097bps in 2026.
  • Cartesian Therapeutics' Net Margin stood at 35.09% in 2022, then tumbled by -6880bps to 2379.12% in 2023, then skyrocketed by 173bps to 1737.8% in 2024, then surged by 207bps to 5335.93% in 2025, then plummeted by -712bps to 32657.69% in 2026.
  • According to Business Quant data, Net Margin over the past three periods came in at 32657.69%, 5335.93%, and 4318.14% for Q1 2026, Q4 2025, and Q3 2025 respectively.